Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 13 hot stocks to buy with the highest upside potential. On January 30, Stifel raised its price target on Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) to $84 from $75, while maintaining its Buy rating, noting that the company’s pre-report for the fourth quarter of 2025 went better than early investor expectations for the first quarter of the launch of Palsonify, an FDA-approved, once-daily oral medication for treating adults with acromegaly.

Meanwhile, in a January 23 report, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) with a price target of $97. Earlier in the month, on January 12, Goldman Sachs upgraded its stock rating on Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) to Buy from Neutral, with a $67 price target, citing positive Phase 2 clinical trial results for the company’s congenital adrenal hyperplasia treatment. The analyst noted that 25% of patients in Cohort 4 of its Phase 2 TouCAHn study have already achieved the primary composite endpoint planned for the Phase 3 trial, which the firm believes has “highly derisked” the upcoming late-stage study’s novel endpoint design.

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) operates as a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Best High-Upside Materials Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.